Sign in to view content

Bevacizumab-First vs Real-World Cost Outcomes for Diabetic Macular Edema: 2-Year Cost Analysis Modeled on DRCR Protocol AC Results

Dilraj S Grewal, MD, FASRS

Video
Published 2023

Related

Genetic Variants Associated With Anti-VEGF Drug Response in Neovascular AMD Patients in the View Trial
Nancy M. Holekamp, MD, FASRS
Updates from the Field
2016
Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Diabetic Retinopathy: The Phase II ALTITUDE® Study
Margaret A. Chang, MD, MS
Updates from the Field
2025
Severity of Diabetic Retinopathy as an Independent Risk Factor for Cerebral Vascular Accidents, Myocardial Infarctions, and All-Cause Mortality
Bobeck S Modjtahedi, MD
Annual Meeting Talks
2020

Category: Socioeconomics

See more